160/4.5 mcg BDF single inhaler therapy vs current best practice
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
1 finding from 1 review
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes onlyOR 2.85 [1.89, 4.3]7 studies · 8411 participantsModerate